MEDNAX, Inc., together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology, pediatric cardiology, and other pediatric subspecialties physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care; and acute and chronic pain management services. The company also provides maternal-fetal care, including inpatient and office-based clinical care to expectant mothers and their unborn babies through maternal-fetal medicine subspecialists, as well as obstetricians and other clinicians consisting of maternal-fetal nurse practitioners, certified nurse mid-wives, ultrasonographers, and genetic counselors. In addition, its pediatric cardiology care services comprise inpatient and office-based pediatric cardiology care of the fetus, infant, child, and adolescent patient with congenital heart defects and acquired heart disease, as well as adults with congenital heart defects through pediatric cardiologist subspecialists and other related clinical professionals. Further, the company provides other pediatric subspecialty care services through pediatric subspecialists, such as pediatric intensivists, pediatric hospitalists, and pediatric surgeons, as well as pediatric ear, nose, and throat physicians; and support services in the areas of hospitals, primarily in the pediatric emergency rooms, labor and delivery areas, and nursery and pediatric departments. Additionally, it provides radiology and teleradiology services. As of December 31, 2017, the company's network consisted of approximately 4,075 affiliated physicians. MEDNAX, Inc. was founded in 1979 and is based in Sunrise, Florida.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Hospitals
Sub-IndustryHealth Care Services
SectorMedical
SymbolNYSE:MD
CUSIP58502B10
Phone954-384-0175
Debt
Debt-to-Equity Ratio0.63
Current Ratio1.74
Quick Ratio1.74
Price-To-Earnings
Trailing P/E Ratio13.51
Forward P/E Ratio11.15
P/E Growth1.11
Sales & Book Value
Annual Sales$3.46 billion
Price / Sales1.20
Cash Flow$4.2943 per share
Price / Cash10.26
Book Value$32.74 per share
Price / Book1.35
Profitability
EPS (Most Recent Fiscal Year)$3.15
Net Income$320.37 million
Net Margins9.34%
Return on Equity10.13%
Return on Assets5.31%
Miscellaneous
Employees7,675
Outstanding Shares94,380,000
Market Cap$4,145.30
MEDNAX (NYSE:MD) Frequently Asked Questions
What is MEDNAX's stock symbol?
MEDNAX trades on the New York Stock Exchange (NYSE) under the ticker symbol "MD."
How were MEDNAX's earnings last quarter?
MEDNAX Inc (NYSE:MD) posted its quarterly earnings results on Monday, April, 30th. The company reported $0.89 EPS for the quarter, topping the consensus estimate of $0.82 by $0.07. The company earned $901.90 million during the quarter, compared to analysts' expectations of $903.75 million. MEDNAX had a net margin of 9.34% and a return on equity of 10.13%. The firm's revenue was up 7.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.75 EPS. View MEDNAX's Earnings History.
When is MEDNAX's next earnings date?
What guidance has MEDNAX issued on next quarter's earnings?
MEDNAX updated its second quarter earnings guidance on Monday, April, 30th. The company provided earnings per share guidance of $1.04-1.09 for the period, compared to the Thomson Reuters consensus estimate of $1.07.
What price target have analysts set for MD?
13 brokers have issued 12-month target prices for MEDNAX's stock. Their forecasts range from $50.00 to $62.00. On average, they expect MEDNAX's share price to reach $55.1538 in the next twelve months. This suggests a possible upside of 25.2% from the stock's current price. View Analyst Ratings for MEDNAX.
What is the consensus analysts' recommendation for MEDNAX?
13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MEDNAX in the last year. There are currently 10 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
Who are some of MEDNAX's key competitors?
Some companies that are related to MEDNAX include Ramsay Health Care Limited Fully Paid Ord. Shrs (RHC), Encompass Health (EHC), Healthscope (HSO), Select Medical (SEM), Magellan Health (MGLN), Primary Health Care (PRY), Medical Facilities (DR), Capitol Health (CAJ), Animalcare Group (ANCR), SunLink Health Systems (SSY), Spine Injury Solutions (SPIN) and THC Biomed Intl (THC).
Who are MEDNAX's key executives?
MEDNAX's management team includes the folowing people:
- Dr. Roger J. Medel, Co-Founder, CEO & Director (Age 71)
- Mr. Joseph M. Calabro, Pres & COO (Age 57)
- Ms. Vivian Lopez-Blanco, CFO & Treasurer (Age 60)
- Mr. Dominic J. Andreano, Sr. VP, Gen. Counsel & Sec. (Age 49)
- Mr. David A. Clark, Pres of Mednax National Medical Group Division (Age 51)
Has MEDNAX been receiving favorable news coverage?
News headlines about MD stock have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm identifies positive and negative news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. MEDNAX earned a coverage optimism score of 0.22 on Accern's scale. They also gave media coverage about the company an impact score of 46.10 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
Who are MEDNAX's major shareholders?
MEDNAX's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Riverbridge Partners LLC (0.85%), Fenimore Asset Management Inc. (0.72%), Bank of Montreal Can (0.22%), Xact Kapitalforvaltning AB (0.02%), Campbell & CO Investment Adviser LLC (0.01%) and State of Alaska Department of Revenue (0.01%). Company insiders that own MEDNAX stock include Cesar L Alvarez, David A Clark, Dominic J Andreano, Enrique Sosa, John C Pepia, Joseph M Calabro, Manuel Kadre, Md Carlo A Waldemar, Md Pascal J Goldschmidt, Paul G Gabos, Robert Irwin Valliant and Vivian Lopez-Blanco. View Institutional Ownership Trends for MEDNAX.
Which major investors are selling MEDNAX stock?
MD stock was sold by a variety of institutional investors in the last quarter, including Riverbridge Partners LLC and Fenimore Asset Management Inc.. Company insiders that have sold MEDNAX company stock in the last year include Cesar L Alvarez, David A Clark, Dominic J Andreano, John C Pepia, Joseph M Calabro and Vivian Lopez-Blanco. View Insider Buying and Selling for MEDNAX.
Which major investors are buying MEDNAX stock?
MD stock was bought by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Campbell & CO Investment Adviser LLC, State of Alaska Department of Revenue, Xact Kapitalforvaltning AB and CHICAGO TRUST Co NA. Company insiders that have bought MEDNAX stock in the last two years include Manuel Kadre and Md Pascal J Goldschmidt. View Insider Buying and Selling for MEDNAX.
How do I buy shares of MEDNAX?
Shares of MD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is MEDNAX's stock price today?
One share of MD stock can currently be purchased for approximately $44.06.
How big of a company is MEDNAX?
MEDNAX has a market capitalization of $4.15 billion and generates $3.46 billion in revenue each year. The company earns $320.37 million in net income (profit) each year or $3.15 on an earnings per share basis. MEDNAX employs 7,675 workers across the globe.
How can I contact MEDNAX?
MEDNAX's mailing address is 1301 CONCORD TERRACE, SUNRISE FL, 33323. The company can be reached via phone at 954-384-0175 or via email at [email protected]
MarketBeat Community Rating for MEDNAX (NYSE MD)
MarketBeat's community ratings are surveys of what our community members think about MEDNAX and other stocks. Vote "Outperform" if you believe MD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MD will underperform the S&P 500 over the long term. You may vote once every thirty days.
